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The objective of this study was to compare the relative cost-effectiveness of two AEDs by a prospective clinical audit. Patients
starting on the adjunctive therapies lamotrigine and topiramate were recruited from the out-patient epilepsy clinics at Queen
Square. Three interview were scheduled: baseline; three months follow-up and six months from baseline. Of the 81 patients
recruited, a total of 73 patients completed all three interviews. An intention to treat analysis was performed on the data. Seizure
severity and frequency were assessed using the National Hospital Seizure Severity Scale. Side-effects, adverse events and reasons
for stopping medication were also recorded.
At the third interview, a total of 47/73 (64%) were still on the prescribed adjunctive drug. Outcome was assessed by two
methods: the > 50% seizure reduction cited in the literature and a more stringent assessment of patient ‘satisfaction’ which we
defined operationally on clinical criteria. Using this definition, a total of 10/73 (14%) patients were ‘satisfied’. The relative costs
of starting patients on each of the two AEDs were calculated, both drug costs and the costs of adverse events (the latter were
defined as events requiring urgent medical attention). The costs of the two drugs were compared. A number of methodological
issues relating to cost comparison are discussed. Outcome and pharmaco-economic studies need to assess more than reduction
in number of seizures. They should take into account variables important for quality of life including side-effects and adverse
events.
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In recent years, the costs of medical care in general,
and the costs of antiepileptic drugs in particular, have
come under close scrutiny1. Whilst approximately 70%
of patients are well controlled on monotherapy, with
standard antiepileptic drugs (AEDs), for the remain-
ing 30% of patients polytherapy is considered. Costs
rise because combinations of AEDs often include the
newer compounds and the unit cost of these is much
greater than that of the older, more established AEDs.
Costs of polytherapy are also higher because of in-
creased side-effects, additional medical interventions
and more extensive drug monitoring.
To assess the cost effectiveness of any intervention,
data are needed for both cost and effectiveness (out-
come) of therapy. Such data on the pharmaco-economic
aspects of medical treatment are, however, extremely
scant. Health economists have attempted to develop
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able supplemented by clinical opinion and including
various assumptions and estimates. Whilst economists’
methods include extensive use of models, it is argued
that the conclusions of such studies are unsatisfactory
and a move away from such modelling in health care
has been predicted2.
Recent studies have attempted to look at the cost
of epilepsy in the UK3 and the cost-effectiveness of
adjunctive therapy in epilepsy4. In both of these stud-
ies, a number of assumptions were made and many of
the costs were estimated. A recent retrospective, cross-
sectional cost-of-illness study, conducted in France,
Germany and the UK, showed that higher seizure fre-
quencies were associated with higher direct and in-
direct costs and with reduced quality of life (QOL)
for patients with epilepsy5. A retrospective audit of
patients starting on lamotrigine showed that, at 6–
8 years follow-up, 86% of those patients still living
were no longer taking these add-on drugs6. In anotherc© 1999 British Epilepsy Association
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in seizure frequency, 36% of patients receiving lam-
otrigine benefitted according to this criterion. These
studies did not take account of side-effects or a broader
appraisal of patient satisfaction.
Topiramate is one of the most recent drugs to be li-
censed as an add-on therapy for the treatment of partial
epilepsies. A double-blind, randomized placebo con-
trolled study suggested that 24% of patients on top-
iramate had a greater than 50% decrease in seizure
frequency8. A high rate of side-effects (41%) was re-
ported, which led to the withdrawal of the drug in 41%
of the patients. In order to explore the potentially in-
teresting clinical differences between topiramate and
lamotrigine, in efficacy and side-effects, we conducted
an audit survey to examine the pharmaco-economic
consequences of their administration in clinical prac-
tice. Our perspective is to compare the reality of clinical
practice with a pharmaco-economic model and to ex-
amine the way that different end-points may lead to
differing drug costs, especially in relation to QOL.
Materials and Methods
Design
Given the limitations of theoretical models, we planned
the current prospective, follow-up study to compare the
outcome of patients starting on two new AEDs (lamot-
rigine and topiramate). Patients were approached after
their medical consultation and the study was explained
to them. For convenience, patients who were willing to
take part were offered the choice of a telephone inter-
view at home as an alternative to a face-to-face inter-
view at the hospital and most patients chose this option.
The timing of the interviews was: (1) baseline; (2) 3
months from baseline and (3) 6 months from baseline.
Main outcome measures
The National Hospital Seizure Severity Scale9 was used
to assess seizure frequency and seizure severity. This
scale is administered by a health professional during
an interview with both patient and a witness to the
seizures. It contains seven seizure-related factors and
generates a score from 1 to 27.
Drug-related sequelae: Side-effects, adverse events
and reasons for stopping medication were also
recorded.
Quality of Life (QOL): QOL was measured by the
QOLAS10, 11 and the EuroQol instrument12 but these
data will be reported elsewhere.
Patient satisfaction: Patients were deemed ‘satisfied’
if they fulfilled all of the following criteria: (1) still ondrug at t D 3; (2) experiencing no side-effects; (3) had
no adverse-events; and (4) had a greater than 50% re-
duction in seizures.
Costs: Patients were asked at follow-up interviews
for dates of stopping medication. Costs for any
epilepsy-related event were included in our analysis.
The costs for the two drugs were found in the current
edition of MIMS13. Costs relating to adverse events
were obtained from the OHE Compendium of Health
Statistics14, from Health Authority sources and other
public bodies as appropriate. Costs were calculated on
an ‘intention to treat’ basis15. For the group of patients
who were lost to follow-up, data concerning their con-
tinuation (or otherwise) with medication were taken
from the patients’ notes. The costs of medication for
these patients could be ascertained and were thus in-
cluded. Data on side-effects and adverse events, how-
ever, were not incorporated since interviews had not
been completed and these data were not systematically
recorded in the patients’ notes.
Costs of ‘adverse events’: In our operational def-
inition of ‘satisfaction’, all epilepsy-related adverse
events were included but, for the cost-effectiveness
comparison, only those events were taken into account
where medical advice was sought and a cost was there-
fore incurred. An example of such an event is the de-
velopment of a skin rash which resulted in extra GP
and/or clinic visits.
Cost-effectiveness comparison: In order to compare
the cost-effectiveness of the different drugs, we used
the cost-effectiveness ratio published in the pharmaco-
economic paper4. The formula used in this paper is as
follows:
CER D Cost per successfully treated patient
D Cost per patient of treatment divided by the
percentage of successfully treated patients.
Results: Part I — Descriptive
A total of 81 adult patients were recruited into the
study. All patients were receiving one or more anti-
convulsants and were prescribed the new medication
because of continuing seizures. Of these, 73 attended
for both follow-up interviews and eight failed to attend
follow-up. Those lost to follow-up were incorporated
and an ‘intention to treat analysis’ was performed15. We
thus report the full outcome of those patients .n D 73/
who started on the two drugs and who completed all
three interviews; the eight patients who were lost to
follow-up are incorporated into the cost-effectiveness
analysis. Of the 73 patients, 26 were started on lam-
otrigine (14 male) and 47 on topiramate (28 male).
Of the eight patients lost to follow-up, six were on
lamotrigine and two on topiramate. There were no sig-
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Table 1: Individual data for patients at the 6 months follow-up.
Topiramate Lamotrigine
Still on drug 31/47 (65%) 16/26 (61%)
Side-effectsa 23/47 (48%) 10/26 (38%)
Adverse eventsb 4/47 (8%) 1/26 (3%)
50% reduction Ss 15/47 (32%) 10/26 (38%)
Number of patients ‘satisfied’c 7/47 (15%) 3/26 (11%)
Seizure-free patients 3/47 (6%) 4/26 (15%)
No interview @ t D 3 2 6
aSide-effects as reported by patients and attributed by them to the
add-on therapy.
bSerious adverse events are epilepsy related requiring urgent
medical care.
cOur operational criteria for ‘satisfied’ were: (1) still on the drug at
t D 3; (2) experiencing no side-effects; (3) had no adverse events;
and (4) had a greater that 50% reduction in seizures.
Table 2: Side-effects reported by patients at t D 2 and/or
t D 3.
Lamotrigine Topiramate
Cognitive effects
Tingling 3
Slowness of thought— 1 2
Judgement impaired 1
Memory 3 6
Speech 1
Stutters 2
Cognitive slowing 3
Headache 2 1
Concentration 1 4
Vision 5 4
Dizzy 1 6
Confusion 2
Mood
Tired 2 8
Depression 1 4
Emotional problems 1
Irritable 1
Tearful 1
Sleepy 1
Fear 1
Short temper 2
Apathy 1
Moody 1
Withdrawn 1
Violent 1
Behavioural
Psychosis 1
Other
Appetite 3
Increase in accidents 1
Stressed 1
Balance 2 2
Constipation 1
Hair loss 1
Weight loss 3
Weight gain 2
Physical harm 1
Bad back 1
Stiffness 1
Bruising 1
Urinary incontinence 1
Rash 3
Table 3: Patients’ stated reasons for stopping drug.
Lamotrigine Topiramate
.n D 10/ .n D 15/
Poor seizure control 2 (20%) 4 (26%)
Cognitive side-effects 0 6 (40%)
Other side-effects 6 (60%) 5 (34%)
Other reasons 2 (20%) 0nificant differences between the mean ages of patients
on the two drugs: lamotrigine mean ageD 37 (SD 9.8);
topiramate mean age D 39 (SD 12.6).
Seizures at baseline
Most of the patients had either non-convulsive seizures
or both convulsions and other seizure types. Of the
73 patients, 39 patients were experiencing convulsions
(53%). The number experiencing convulsions for each
drug was lamotrigine D 13 (50%) and topiramate
D 26 (55%).
Status at 3 months follow-up
At 3 months follow-up, 21 were still on lamotrigine
(81%) and 31 remained on topiramate (66%).
Status at 6 months follow-up
At the last follow-up, 16 (61%) of the patients were
still on lamotrigine 31 (66%) on topiramate. Table 1
shows individual data for the 73 patients at 6 months
follow-up. The side-effects reported by the patients are
shown in Table 2. Reasons for stopping the drugs at
any point are given in Table 3.
Results: Part 2 — Costings (drugs
and indirect costs)
The costs of the drugs for each patient, on an inten-
tion to treat basis, for the 6 month period are shown
in Table 4. This table shows two alternative costs for
topiramate: the first includes all epilepsy related costs,
and the second costing shows this sum minus the costs
for admission for elective, in-patient video-telemetry.
These costs, concerning only three patients, greatly
inflated the total cost for topiramate. No patient in thelamotrigine group had undergone video-telemetry dur-
ing the study. The total costs divided by the number of
patients ‘satisfied’ are shown in Table 5. In Table 6 we
compare the cost-effectiveness of these drugs.
Table 7 shows the differences in the costing of the
two drugs when we compare a conventional measure of
successful treatment (a > 50% reduction in seizures),
with our more stringent outcome of patient ‘satisfac-
tion’.
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Table 4: Costs, for the 6 month period, of starting patients on
each of the drugs.
Drug therapy Adverse Total Cost per
events cost patient
Topiramate £14 745 £556a £20 088 £35 389 £722
n D 47 n D 2
Topiramateb
(without £14 745 £556a £7813 £23 114 £472
telemetry n D 47 n D 2
unit costs)
Lamotrigine £10 111 £1377a £7303 £18 791 £587
n D 26 n D 6
aCost for patients who did not complete full follow-up interviews at 6
months.
bThis is the cost for topiramate minus the costs for the patients having
in-patient telemetry. No patients on lamotrigine incurred a telemetry cost.
Table 5: Cost of patients on each drug, divided by number of
patients ‘satisfied’ at the end of the 6 months follow-up period.
Number Percentage Total cost divided
satisfied satisfied by number of
‘satisfied’pts
in each drug
Topiramate 7 14 £5055
.n D 49/
Topiramate (without 7 14 £3302
telemetry cost)
.n D 49/
Lamotrigine 3 9 £6263
.n D 32/
Table 6: Cost effectiveness (C/E) comparison of each of the
drugs.
Cost per patient Percentage C/E
satisfied
Lamotrigine £587 2 D 1174/ 9 D £130
Topiramate £472 2 D 944/ 14 D £67
(without
telemetry costs)
Table 7: Cost per patient: difference between ‘satisfied’ and
50% seizure reduction.
Lamotrigine Topiramate
without telemetry
‘Satisfied’ £6263 n D 3.9%/ £3302 n D 7.14%/
50% seizure £1879 n D 10.31%/ £1541 n D 15 (31%)
reductionSensitivity analysis
We did not perform a sensitivity analysis because we
are presenting actual, prospective, clinical data. We do,
however, discuss the methodological issues concerning
what costs to include and we present data both includ-
ing and excluding the cost of an elective, in-patient
admission. Since our paper is already concerned with
questions of methodology, our conclusions are tentative
and these data do not lend themselves to the systematic
calculation of uncertainty. Moreover, the methods of
sensitivity analysis remain relatively underdeveloped
and the subject of some debate16.Discussion
In this study we have carried out an audit of patients
treated with one of two new anticonvulsant drugs.
The drugs were added to existing medications in pa-
tients with difficult to control seizures. The situation
with monotherapy may be different, but to date most
patients given these drugs receive them as polyther-
apy.
The study is not a double-blind or back-to-back
comparison and we acknowledge that such studies are
needed and important. However, we are presenting em-
pirical data, derived from clinical experience, and based
upon careful follow-up over 6 months. Nearly all of
the follow-up studies that are published concentrate
on seizure reduction as the outcome measure. Further,
most studies, following initial investigations carried out
for the purpose of drug regulation, are retrospective in
design17. Here, we have attempted to achieve two out-
comes: first, a prospective evaluation and, second, to
incorporate measures of patient satisfaction into our
follow-up which we believe are more important indi-
cators of outcome above and beyond simple measures
of reduction of seizure frequency, the usual variable
measured.
We have used some objectively defined methods of
assessment (The National Hospital Seizure Frequency
and Severity scale and the EQ-5D), but we have also
conducted in-depth interviews inviting patients to dis-
cuss their feelings about their treatment and their re-
sponses to various side-effects. All of the interviews
were carried out by a single interviewer using a proto-
col to ensure consistency of data elicitation. Of the pa-
tients who were still on the drug at 6 months follow-up,
only 14% were ‘satisfied’ according to our operational
definition.
We compare the figure obtained using this measure
of outcome with the figure obtained using the more usu-
ally reported measure of outcome, namely a decrease
in seizure frequency. While many studies identify the
number of patients who have achieved a reduction in
seizure frequency, few emphasize QOL measures or
patient satisfaction.
In another study18, we have shown that our patient-
specific measures of ‘satisfaction’ are significantly as-
sociated with an improvement in QOL. The fact that
we found only 14% of patients ‘satisfied’ might ex-
plain why Walker et al.6 found that 86% of patients
(6–8 years follow-up) had stopped taking their new an-
ticonvulsant drugs.
The data at first follow-up indicate that more pa-
tients on topiramate experience side-effects and ad-
verse events. However, comparing the two drugs at
6 months follow-up, the number of patients with
50% reduction in seizures and the number of pa-
tients ‘satisfied’ is very similar. We acknowledge
12 C. E. Selai et al.
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It could be argued that our definition of ‘satisfied’
is too exacting. The most controversial aspect would
be the inclusion of side-effects as well as more sig-
nificant adverse events in this measure. However, the
clinical reality is that patients are concerned about the
side-effects of drugs, want to discuss them with the re-
searcher, and it is now established that they are a central
feature of QOL, and satisfaction with treatment, for pa-
tients taking these drugs19.
Pharmaco-economic analysis
The importance of pharmaco-economic analyses is ac-
knowledged but such studies are in their infancy. We
have previously presented data based on a theoreti-
cal model4 of the pharmaco-economic differences be-
tween several anticonvulsant drugs20. From this model
we have taken our cost-effectiveness ratio. However,
the results of this previous study show how inaccu-
rate pharmaco-economic models can be when com-
pared with clinical reality20. Regarding our pharmaco-
economic audit, we would make the following points.
First, we have considered the cost of prescribing each
of the two drugs as an add-on therapy. This is based
upon an intention to treat analysis and is conceptually
different from merely working out the actual cost of
the drug per patient followed to the end of the study.
We therefore take into consideration the full epilepsy-
related costs that arise from an initial prescription for
each drug which includes the cost of those that drop out
of the study (as far as costing the latter was possible).
Second, we have tried to consider what costs should
actually be included in a disease-related pharmaco-
economic study. There are no gold standards21. At
the outset we decided to include every epilepsy-related
event that occurred during the course of the drug treat-
ment. This decision resulted in more than just direct
drug-related (usually adverse) events being costed.
It became apparent when we started to analyse our
data that three patients in the topiramate group, but
none in the lamotrigine group, had spent a period of
time having in-patient telemetry as an elective pro-
cedure, either at the National Hospital or the Chal-
font Centre for Epilepsy. We show how including
such an epilepsy-related expense dramatically alters
the pharmaco-economic costings. The issue of which
disease-specific costings should go into an analysis is
in need of clarification.
Third, we show the dramatic differences between
simply presenting pharmaco-economic data as cost per
patient treated, compared to cost for reducing seizures
by > 50%, compared to cost per patient ‘satisfied’. Ifwe just considered the cost of a patient becoming 50%
seizure free, without indices of satisfaction (Table 7)
the costs drop considerably.
Fourth, we have used a formula for cost-effectiveness
taken from our pharmaco-economic study4. In that
study, the period under consideration was 12 months
and we adjusted our data to make them comparable to
the published data for a 1 year period. This may have in-
fluenced our cost-effectiveness ratios. However, when
we compare the cost-effectiveness ratios between the
drugs in this study, there are clearly substantial differ-
ences and it is unlikely that our adjusting the data in
this way accounts for such findings. Again, there are
no gold standards but this may be a useful way of ex-
amining differences between drugs for future studies.
Conclusions
We present data from an audit of two new anticonvul-
sant drugs conducted at a tertiary referral centre to look
at treatment satisfaction. Our data suggest that only
a minority of patients with intractable epilepsy going
on to the newer anticonvulsants derive ‘satisfaction’
from these drugs when given as an add-on therapy. We
have highlighted differences in costs of achieving pa-
tient ‘satisfaction’ between lamotrigine and topiramate
which may have relevance for the prescribing of these
drugs.
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